Traws Pharma, Inc. announced the appointment of Luba Greenwood as a new Director to its Board, effective September 20, 2024. Concurrently, James J. Marino stepped down from the Board after nearly ten years of service, including four years as Chairman.
Ms. Greenwood brings extensive experience as an investor, board member, and executive in the life sciences industry, including roles as Managing Partner of Binney Street Capital (BSC) and Vice President of Global Business Development and M&A at Roche. Her expertise is expected to support Traws' ongoing transformation and growth.
The company's Executive Chairman, Iain Dukes, stated that Ms. Greenwood's considerable expertise in strategy, corporate development, and corporate governance will be valuable as Traws advances its novel respiratory antiviral therapies through Phase 1 studies and progresses its oncology strategy.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.